All ALK fusions took place at the 5’ end of the protein and breakpoints in intron 19 were highly recurrent, accounting for 95% overall, 96% in lung cancers and 81% in non-lung cancers, producing fusion products fused to exon 20 of the ALK gene (Fig. 2a). This evidence concerns the gene ALK and lung carcinoma.